Finance News – Astrazeneca
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure
AstraZeneca’s leadership suggested lowering prices on certain medications in the U.S., aiming to address market challenges and regulatory pressures affecting the company’s revenue...
Read Full Article →Could Astrazeneca completely switch its allegiance to the US?
AstraZeneca’s potential shift toward US markets reflects broader concerns about economic incentives and growth prospects, highlighting the impact of regional financial environments...
Read Full Article →Ministers take note: now is the moment to fight to keep AstraZeneca’s listing in London | Nils Pratl...
AstraZeneca’s growing US market presence and substantial investment plans highlight the potential impact on its stock listing decisions and overall financial strategy in the coming...
Read Full Article →AstraZeneca chief executive hails ‘vital importance of US’ as Trump tariffs loom
AstraZeneca’s planned multibillion-dollar investment in the United States highlights the country’s strategic value to the company amid potential trade restrictions and ongoing mark...
Read Full Article →AstraZeneca Stock Rises as US, Cancer Drugs Growth Lifts Q2 Results
AstraZeneca's financial performance improved in the second quarter, driven by increased demand in the US market and strong sales of oncology medications, positively influencing its...
Read Full Article →AstraZeneca reports higher sales on record US growth
AstraZeneca's revenue increased due to strong performance in the US market, coinciding with the company's announcement of a $50 billion investment to address potential challenges f...
Read Full Article →Astrazeneca: Demand for cancer drugs boosts pharmaceutical giant
AstraZeneca experienced an 11 percent increase in total revenue to $28 billion in the first half, largely due to strong sales growth in its cancer treatment and biopharmaceutical s...
Read Full Article →AstraZeneca will invest $50 billion in the U.S. as it seeks to avoid Trump's tariffs
AstraZeneca plans to allocate $50 billion toward expanding operations in the United States, aiming to generate tens of thousands of skilled employment opportunities while minimizin...
Read Full Article →AstraZeneca pledges $50bn investment in the US amid 200% tariff fears
AstraZeneca plans a substantial investment in the United States to strengthen its market position and address concerns about potential import costs affecting its profitability.
Read Full Article →AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats
AstraZeneca plans to allocate $50 billion over the next decade to enhance manufacturing and research capabilities across multiple US states, reflecting a strategic commitment amid...
Read Full Article →Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks
Summit Therapeutics experienced a significant increase in its share value following news of potential collaboration discussions with AstraZeneca valued at around $15 billion.
Read Full Article →Investors fret on talk of AstraZeneca US move
Concerns have grown among shareholders about the potential impact on the UK market and investment stability if AstraZeneca relocates its operations to the United States.
Read Full Article →If AstraZeneca goes to the US, it will be a major blow for London and Labour
Relocating AstraZeneca's headquarters to the United States could significantly impact London’s financial markets and challenge the stability of current government plans supporting...
Read Full Article →Losing AstraZeneca would be more than a bitter pill for the City – it could be fatal
The potential departure of AstraZeneca from the London Stock Exchange poses a serious financial threat, highlighting the need for government reforms to maintain the market’s compet...
Read Full Article →AstraZeneca boss ‘wants to shift stock market listing to US’
The potential relocation of AstraZeneca’s equity listing to the United States could impact investor access, market perception, and the company’s regulatory and financial reporting...
Read Full Article →Astrazeneca chief ‘wants to shift London listing to US’
Relocating the company’s stock exchange registration to the United States could potentially enhance access to larger capital markets and increase investor exposure for the pharmace...
Read Full Article →Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting close...
Pharmaceutical companies are advancing the development of specialized cancer treatments, potentially reducing reliance on chemotherapy and driving significant market growth through...
Read Full Article →FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck’s newly authorized RSV vaccine for infants is expected to impact the market by challenging established treatments, potentially influencing sales and market share among leadin...
Read Full Article →GSK and Astrazeneca shares slump as Trump vows drug price cut
The announcement of new executive measures aimed at lowering medication costs has led to a decline in the stock values of major pharmaceutical companies, reflecting investor concer...
Read Full Article →FTSE 100’s record run fades as pharma stocks slide on new Trump appointment
The decline in major pharmaceutical shares contributed to a modest drop in the FTSE 100, signaling potential market uncertainty linked to changes in US regulatory leadership.
Read Full Article →